FERM, ARH/RhoGEF and pleckstrin domain protein 2Genealiases: FIR · FRG · PLEKHC3
Q-omics provides the consensus-scored FARP2 profile across patient tissues and cancer cell-line models. FARP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FARP2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, FARP2 RNA expression shows 21,229 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where FARP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FARP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FARP2 survival associations across molecular data types. FARP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FARP2 RNA expression–survival associations across cancer types. High FARP2 expression shows unfavorable associations in MESO, ACC, KIRP, LGG and LIHC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FARP2 RNA expression.
This table summarizes FARP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FARP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FARP2 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, STAD and LUSC. The THCA box plot shows higher FARP2 RNA expression in normal versus tumor tissue (log2 FC = −0.728, t-test p < 0.001).
This table shows molecular features associated with FARP2 in patient tissues and cancer cell lines. In patient samples, FARP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FARP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
